Facebook
Twitter
LinkedIn
ForwardThe Path to Least Resistance: The Emerging Role of Noncovalent BTK Inhibitors in CLL/SLL Across Clinical Practice Settings
Program Description
The advent of covalent Bruton’s tyrosine kinase inhibitors (cBTKi) (e.g., ibrutinib) in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) has significantly enhanced long-term outcomes and quality-of-life for patients as the treatment landscape continues to shift away from traditional chemoimmunotherapy approaches. However, many patients eventually develop treatment resistance, driving disease progression and further limiting therapeutic options. As a result, noncovalent BTKis (ncBTKi) have emerged with their first-in-class approval, pirtobrutinib, entering the space in late 2023 and more following close behind under late-stage investigation. These agents are designed to overcome resistance mechanisms associated with exposure to cBTKi and provide another treatment path for patients. Join a faculty panel of both community- and academic-based hematologic oncologists as they utilize their perspectives and real-world experiences to provide insights on the optimal integration of novel ncBTKi in CLL/SLL across clinical practice settings.
Target Audience
The target audience for this initiative includes oncologists, hematologists, advanced practice professionals, nurses, and pharmacists working in oncology care settings.
Learning Objectives
Upon completion of the educational activity, participants should be able to:
- Identify strategies for overcoming resistance to BTKi therapy to optimize treatment selection for patients with CLL/SLL
- Differentiate the mechanisms of action, clinical efficacy, and safety of covalent and novel noncovalent BTKi to appropriately position these agents within the CLL/SLL treatment armamentarium
- Employ multidisciplinary strategies for managing adverse events (AEs) in patients receiving BTKi therapy to optimize patient outcomes in CLL/SLL across clinical practice settings
Jennifer A. Woyach, MD (Chair)
Lindsey Roeker, MD
Sunil M. Patel, MD, MBA
Jose Sandoval-Sus, MD, FACPThis activity is jointly provided by Partners for Advancing Clinical Education (PACE) and Efficient LLC.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Efficient LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Designation Statement
PACE has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credits. Approval is valid until July 20, 2025. PAs should only claim credit commensurate with the extent of their participation.Faculty and Disclosure of Conflicts of Interest
PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.
The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The Efficient LLC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Commercial Support
This activity is supported by an educational grant from Lilly.
Available Credit
- 1.00 AAPA Category I CME
- 1.00 AMA PRA Category 1 Credit™